THE metabolic mechanism by which tryptophan is converted into nicotinic acid appears to be altered in several human diseases. Yet it has not been possible to demonstrate specific excretory patterns for the various diseases. The excretory pattern in the urines of patients with cancer of the bladder is certainly the one which presents the most specific and relevant alterations (Quagliariello, 1963).
20 ml. of all the urines collected during the day were acidified with acetic acid (1: 1) and centrifuged at low speed. Charcoal deactivated with 4 per cent by weight of stearic acid was added to the supernatant and the mixture shaken for 5-10 minutes. The charcoal was filtered off and washed with water to remove the remaining salts, urea, sugars and aliphatic aminoacids. It was then eluted with saturated aqueous phenol solution, previously heated at 400. The phenol eluates were evaporated to dryness under vacuum at 50-600. The residues were taken up in 0 5 ml. water; of this 0-2 ml. were spotted on Whatman No. 1 paper. Two-dimensional descending runs were performed. The solvent for the first run was the organic phase from a freshly prepared mixture of butanol: acetic acid: water (4: 1:5; v/v).
Glass-bidistilled water was used for the second run. Tryptophan metabolites were identified by fluorescence under ultraviolet light (3660 A) and by characteristic colour reactions (ninhydrin reaction, Ehrlich's reagent, ammoniacal silver nitrate; see Quagliariello et al., 1961) . Reference standards of 3-hydroxyanthanilic acid and other tryptophan metabolites were run simultaneously.
Determination of 3-hydroxyanthranilic acid.-The pieces of paper corresponding to the spots of 3-hydroxyanthranilic acid were cut out and eluted with 01 M potassium-phosphate buffer pH 7-5. To 5 ml. of the eluate in test-tubes fitted with ground-glass stoppers, were added: 4f5 ml. citrate-phosphate buffer pH 4.5, 0*5 ml. sodium carbonate (5 per cent), 2 ml. diazotized sulphanilic acid (0.5 per cent in 2 per cent HC1, mixed, before using, with an equal volume of sodium nitrite, 0 5 per cent in water; this last operation was carried out at 00). The mixture was incubated for 30 minutes at 150. The 3-hydroxyanthranilic acid concentration was calculated measuring the O.1D. at 450 m,t. The sensitivity ranged between 1-50 ,ug. 3-hydroxyanthranilic acid/12 ml. final volume in testtube.
RESULTS AND DISCUSSION
In Table I is reported the daily excretion of 3-hydroxyanthranilic acid in normal subjects and in patients with bladder cancer. From the values shown it appears evident that the subjects with primary carcinoma of the bladder excreted larger amounts of 3-hydroxyanthranilic acid than the normals. Table II shows the daily excretion of 3-hydroxyanthranilic acid in the urine of patients with pelvic and extra-pelvic kidney tumours. It appears that 3-hydroxyanthranilic acid is always present in the urine of patients with primary carcinomas of the renal pelvis. Thus 3-hydroxyanthranilic acid appears to be constantly present in the urines of patients with primary carcinomas of the urinary tracts. Very recently Benassi, Perissinotto and Allegri (1963) reported that 3-hydroxyanthranilic acid is excreted in large amounts in the urine of most of the cases of renal carcinoma they examined. Yet these authors did not find 3-hydroxyanthranilic acid in bladder cancer.
As regards the factors responsible for the increased excretion of 3-hydroxyanthranilic acid in the patients with carcinomas of the urinary tracts, we maintain that it depends essentially upon an alteration of tryptophan-nicotinic acid interrelationship. It may be that this increased excretion of 3-hydroxyanthranilic acid also depends, either upon an increase of ,8-glucuronidase activity (Boyland, I Samples 9', 9" and 10', 10" came from two patients; samples 9' and 10' were collected without special precautions and were kept at -20°C. ; samples 9" and 10" were collected in ethanol (1: 4 ; v: v) in order to prevent the enzymic hydrolysis of 3-hydroxyanthranilic acid conjugates. Number 19 refers to a case of prostatic carcinoma with bladder metastasis. 1958, 1963) or upon an increased rate of tryptophan metabolism via kynurenine. An increase of,?-glucuronidase cannot easily explain the presence of free 3-hydroxyanthranilic acid in the urine of patients with carcinomas of the renal pelvis. If the second hypothesis were correct, the urines would show an increased excretion of all the intermediates, especially the last ones of the series (the excretion products of nicotinic acid). Price, Wear, Brown, Satler and Olson (1960) and Price and Brown (1962) reported the values for excretion of tryptophan metabolites under normal conditions and after a 2 g. loading dose of tryptophan in normal controls and in patients with bladder cancer. The excretion of N-mnethyl-2-pyridone-5-carboxyamide (the main urinary excretion product of nicotinic acid) was the same in both cases. SUMMARY 3-Hydroxyanthranilic acid urinary excretion has been studied in normals and in patients with tumours of the kidney and bladder. In patients with primary carcinomas of the urinary tract the quantity of 3-hydroxyanthranilic acid excreted daily appeared to be greater than in normal controls.
